CRYOFOCUS MEDTECH (SHANGHAI) CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.91 HKD | +8.48% |
|
+7.97% | -63.28% |
| Mar. 27 | Cryofocus Medtech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 15 | Cryofocus Medtech Gets Marketing Approval in China for Cryoadhesion System | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 3,729 | 4,090 | 1,533 | - | - |
| Enterprise Value (EV) 1 | 3,729 | 4,090 | 1,533 | 1,533 | 1,533 |
| P/E ratio | - | -41.7 x | -22.5 x | -107 x | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 137 x | 99.9 x | 8.94 x | 4.37 x | 2.59 x |
| EV / Revenue | 137 x | 99.9 x | 8.94 x | 4.37 x | 2.59 x |
| EV / EBITDA | - | -39.2 x | -27.1 x | 377 x | 12.8 x |
| EV / FCF | - | - | -17.5 x | -55.3 x | 25.7 x |
| FCF Yield | - | - | -5.71% | -1.81% | 3.89% |
| Price to Book | - | 25.3 x | 18.9 x | 22.1 x | - |
| Nbr of stocks (in thousands) | 239,110 | 239,110 | 239,110 | - | - |
| Reference price 2 | 15.60 | 17.11 | 6.410 | 6.410 | 6.410 |
| Announcement Date | 3/30/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | 27.15 | 40.95 | 171.5 | 350.5 | 591.4 |
| EBITDA 1 | - | -104.4 | -56.49 | 4.07 | 119.7 |
| EBIT 1 | - | -105.1 | -71 | -15.15 | 99.4 |
| Operating Margin | - | -256.64% | -41.4% | -4.32% | 16.81% |
| Earnings before Tax (EBT) 1 | - | -105.7 | -71.64 | -15.85 | - |
| Net income 1 | -112.2 | -97.49 | -67.94 | -15.04 | - |
| Net margin | -413.36% | -238.06% | -39.62% | -4.29% | - |
| EPS 2 | - | -0.4100 | -0.2850 | -0.0600 | - |
| Free Cash Flow 1 | - | - | -87.44 | -27.72 | 59.61 |
| FCF margin | - | - | -50.99% | -7.91% | 10.08% |
| FCF Conversion (EBITDA) | - | - | - | - | 49.79% |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/30/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -87.4 | -27.7 | 59.6 |
| ROE (net income / shareholders' equity) | - | -48.7% | -47.2% | -13.1% | - |
| ROA (Net income/ Total Assets) | - | -37% | -30.3% | -6.65% | - |
| Assets 1 | - | 263.3 | 224.1 | 226.3 | - |
| Book Value Per Share 2 | - | 0.6800 | 0.3400 | 0.2900 | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 15.9 | 29.7 | 33.9 |
| Capex / Sales | - | - | 9.28% | 8.48% | 5.73% |
| Announcement Date | 3/30/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.41
CNY
Average target price
25.57
CNY
Spread / Average Target
+298.96%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -63.28% | 212M | |
| +43.64% | 754B | |
| +39.42% | 630B | |
| -6.58% | 352B | |
| +19.72% | 331B | |
| +8.78% | 298B | |
| +11.92% | 217B | |
| -2.62% | 216B | |
| +0.03% | 163B | |
| +6.13% | 164B |
- Stock Market
- Equities
- 6922 Stock
- Financials Cryofocus Medtech (Shanghai) Co., Ltd.
